# Consortium of Eosinophilic Gastrointestinal Disease Researchers

> **NIH NIH U54** · CINCINNATI CHILDRENS HOSP MED CTR · 2022 · $1,449,842

## Abstract

Project Summary (Overall)
This renewal application aims to continue research on rare eosinophilic gastrointestinal diseases with a focus
on eosinophilic esophagitis (EoE), eosinophilic gastritis (EG), eosinophilic gastroenteritis (EGE), and eosinophilic
colitis (EC) through the Consortium of Eosinophilic Gastrointestinal Disease Researchers (CEGIR). CEGIR will
promote highly collaborative, multi-site, patient-centric, translational, and clinical research with the intent of
addressing unmet clinical trial readiness needs. CEGIR comprises clinical centers in Ohio (coordinating center),
Colorado, Arkansas, California, Illinois, Maryland, Massachusetts, Minnesota, New York, North Carolina,
Pennsylvania, Tennessee, Texas, and Utah. The CEGIR sites have been carefully chosen on the basis of their
pre-existing record of collaboration and success with each other before and during the first cycle of CEGIR;
diverse expertise in relevant clinical specialties including Gastroenterology, Allergy, Immunology, Nutrition, and
Pathology; the ability to integrate pediatric and adult patients into a common consortium; well-established record
of excellence in clinical and translational research involving this patient population; and excellent mentorship
experience and capacity to impact early stage trainees’ career development. CEGIR sites have proven access
to an adequate number of patients with EoE, EG, EGE, and EC, as evidenced from completion of several
controlled clinical trials involving these patients. Proactive patient advocacy groups (PAGs), including the
American Partnership for Eosinophilic Disorders and the Campaign Urging Research for Eosinophilic Disease,
partner synergistically in the context of CEGIR. Though still in a relatively early stage, CEGIR is demonstrating
success via its collaborative interactions between investigators (at all stages of career development including
newly established promising faculty who represent the next generation of thought leaders), highly engaged
PAGs, and partnering institutions and has emerged into the leading research group focused on rare EoE, EG,
EGE, and EC. Current and proposed CEGIR initiatives are developing clinical trial readiness for this set of rare
diseases, such as the establishment of deeply phenotyped and genotyped patients who are ready to participate
in research and emerging tools that quantify clinical states, endoscopic abnormalities, tissue pathology, and
patient well-being. In this renewal application, investigators plan to study an already developed observational
cohort of patients, providing a valuable opportunity for longitudinal analyses. Data emerging from this cohort has
already substantiated the association of type 2 allergic immunity (e.g. IL-13) in the pathogenesis of EG, leading
to a proposal, described herein, to examine the impact of a promising new anti-type 2 immunity
therapeutic (dupilumab, anti-IL-4Ra). CEGIR includes transformative Pilot-Feasibility and Career Enhancement
Cores ...

## Key facts

- **NIH application ID:** 10478127
- **Project number:** 5U54AI117804-09
- **Recipient organization:** CINCINNATI CHILDRENS HOSP MED CTR
- **Principal Investigator:** Marc E. Rothenberg
- **Activity code:** U54 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $1,449,842
- **Award type:** 5
- **Project period:** 2014-08-15 → 2024-08-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10478127

## Citation

> US National Institutes of Health, RePORTER application 10478127, Consortium of Eosinophilic Gastrointestinal Disease Researchers (5U54AI117804-09). Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/grant/nih/10478127. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*